<DOC>
	<DOCNO>NCT02992457</DOCNO>
	<brief_summary>Egypt high prevalence hepatitis C virus ( HCV ) world , estimate nationally 14.7 % . Genotype 4 ( subtype 4a particular ) dominate HCV epidemic Egypt . For decade antiviral therapy chronic HCV infection base administration Interferon ( IFN ) , initially alone combination Ribavirin ( RBV ) , regimen effective 50 % patient genotype 1 , significant side effect .</brief_summary>
	<brief_title>Safety Efficacy Sofosbuvir-Based Regimens Treatment Egyptian Patients With Post-hepatitis C Cirrhosis</brief_title>
	<detailed_description>Egypt high prevalence hepatitis C virus ( HCV ) world , estimate nationally 14.7 % . Genotype 4 ( subtype 4a particular ) dominate HCV epidemic Egypt . For decade antiviral therapy chronic HCV infection base administration ofInterferon ( IFN ) , initially alone combination Ribavirin ( RBV ) , regimen effective 50 % patient genotype 1 , significant side effect . The introduction direct act antiviral agent , particular sofosbuvir ( SOF ) , revolutionize treatment chronic hepatitis C virus .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>• HCV infection Adult patient , 18years old . • Child score &gt; 12 Severe Renal impairment Pregnant lactate woman HCC malignant neoplasms Coinfection human immunodeficiency virus ( HIV ) Coinfection hepatitis B virus ( HBV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>